Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Romanos Sklavenitis-Pistofidis

Romanos Sklavenitis-Pistofidis

Dana-Farber Cancer Institute
Findings from a sequencing study evaluating tumor & immune cells in pts with MGUS, SMM & myeloma 3:14
Findings from a sequencing study evaluating tumor & immune cells in pts with MGUS, SMM & myeloma
Romanos Sklavenitis-Pistofidis • 13 Mar 2025
Single-cell RNA-sequencing of 6 million tumor and immune cells from patients with MGUS and SMM 4:18
Single-cell RNA-sequencing of 6 million tumor and immune cells from patients with MGUS and SMM
Romanos Sklavenitis-Pistofidis • 7 Dec 2024
A single-cell RNA analysis of tumor and immune cells in asymptomatic and overt WM 4:19
A single-cell RNA analysis of tumor and immune cells in asymptomatic and overt WM
Romanos Sklavenitis-Pistofidis • 18 Oct 2024
Sub-typing Waldenström’s macroglobulinemia: memory B-cell subtype and plasma cell-like subtype 1:51
Sub-typing Waldenström’s macroglobulinemia: memory B-cell subtype and plasma cell-like subtype
Romanos Sklavenitis-Pistofidis • 18 Oct 2024
Improving the risk stratification of patients with smoldering myeloma 1:53
Improving the risk stratification of patients with smoldering myeloma
Romanos Sklavenitis-Pistofidis • 26 Sep 2024
Single-cell RNA sequencing of tumor and immune cells in patients with plasma cell premalignancy 1:51
Single-cell RNA sequencing of tumor and immune cells in patients with plasma cell premalignancy
Romanos Sklavenitis-Pistofidis • 26 Sep 2024
Identifying immune biomarkers of progression in patients with HR-SMM treated with immunotherapy 3:38
Identifying immune biomarkers of progression in patients with HR-SMM treated with immunotherapy
Romanos Sklavenitis-Pistofidis • 16 Dec 2022
Using single-cell RNA sequencing to identify immune dysregulation in patients with MGUS and SMM 3:25
Using single-cell RNA sequencing to identify immune dysregulation in patients with MGUS and SMM
Romanos Sklavenitis-Pistofidis • 16 Dec 2022
Smoldering myeloma: the challenges of ‘watch and wait’ versus early intervention 1:44
Smoldering myeloma: the challenges of ‘watch and wait’ versus early intervention
Romanos Sklavenitis-Pistofidis • 16 Dec 2022
Risk stratification model for asymptomatic Waldenström’s macroglobulinemia 6:33
Risk stratification model for asymptomatic Waldenström’s macroglobulinemia
Romanos Sklavenitis-Pistofidis • 1 Nov 2022
Single-cell RNA sequencing of BM and PB samples from patients with high-risk smoldering myeloma 2:57
Single-cell RNA sequencing of BM and PB samples from patients with high-risk smoldering myeloma
Romanos Sklavenitis-Pistofidis • 25 Aug 2022
Progression risk stratification of asymptomatic WM 3:23
Progression risk stratification of asymptomatic WM
Romanos Sklavenitis-Pistofidis • 14 Sep 2019
Founding precision therapy for 1q-amplified multiple myeloma 2:13
Founding precision therapy for 1q-amplified multiple myeloma
Romanos Sklavenitis-Pistofidis • 14 Sep 2019
The content of VJHemOnc is intended for healthcare professionals